Key result
National and European health policies are needed to ensure patients and families affected by cardiomyopathies have access to multidisciplinary expert care, genetic testing, and holistic support.
Why the study?
Despite new ESC guidelines, cardiomyopathies are often overlooked in policy efforts, and patients' and families' access to multidisciplinary care and genetic services varies widely across Europe depending on health system factors.
National and European health policies must prioritize multidisciplinary care, genetic testing, and holistic support for patients with cardiomyopathies and their families.
Answers are grounded in this paper and cite their sources.
Supports immediate national CVD action plans across Europe; extends meta-analytic evidence on policy gaps to guide coordinated implementation.
Cardiovascular diseases are currently the focus of mounting calls for increased health policy attention in many European countries and European level, being the leading cause of death across Europe and conferring an enormous economic burden—recently estimated at €282 billion annually across the European Union (EU).1 That said, not all countries have a national cardiovascular action plan and gaps exist in those that do. While policy efforts rightly place a major focus on the prevention of acquired age-related conditions, cardiomyopathies—i.e. primary myocardial diseases—are often overlooked. Cardiomyopathies, which are often inherited,2 are far from rare with prevalence rates for the most common forms as high as 1/250.3 Cardiomyopathies can increase the risk of sudden cardiac death, cause incapacitating symptoms, impair the quality of life of patients and families, and are a leading reason for heart transplantation in the very young. Healthcare costs are often high, especially when patients need to be hospitalized.4 New clinical guidelines published by the European Society of Cardiology (ESC) offer an unprecedented opportunity to improve the standards of cardiomyopathy care across Europe.2 However, patients’ and families’ access to such care depends heavily on policy and health system factors that can vary between and within countries. These policy factors include support for expert centre networks, screening programmes, and reimbursement of guideline-recommended tests (Table 1). Landscape of national policies relating to patient care and family screening for inherited cardiomyopathies This table summarizes current governmental and health system-level policies, actions, and initiatives led, co-ordinated, or funded by the national health ministry, National Health Service, or national research funding body, as appropriate. We recognize that relevant additional initiatives led or funded by other stakeholders (including scientific and professional societies, patient organizations, and charities) exist in some countries. ARVC, arrhythmogenic right ventricular cardiomyopathy; CM, cardiomyopathy; CVD, cardiovascular disease; HCM, hypertrophic cardiomyopathy; NCD, non-communicable diseases; NHS, National Health Service; SCD, sudden cardiac death. Here, we offer national-level policy recommendations to help ensure that all patients and families affected by cardiomyopathies have access to guideline-led care (Figure 1). These are based on a Policy Roadmap developed by Cardiomyopathies Matter, a multi-stakeholder initiative launched in 2022 that aims to raise awareness of cardiomyopathies among policymakers and to ensure these health conditions are given the policy attention they warrant both at national and European levels (www.cardiomyopathiesmatter.eu).2 Summary of measures that national-level policy and health system decision-makers should implement to improve care and support for patients affected by cardiomyopathies and other inherited cardiovascular diseases. These include measures at key stages of the care pathway (diagnosis, referral, and disease management) and those that apply throughout all stages (holistic support for, and empowerment of patients and carers, and research and innovation) All patients with cardiomyopathy should have prompt access to well–co-ordinated, multidisciplinary expert care—with ‘the family at its heart’.2 Fundamental to patients’ access are measures to ensure that primary care professionals (to whom patients with suspected cardiomyopathies may first present) have appropriate education and decision support tools and are supported to deliver regular cardiovascular health checks based on a life-course approach. Policy actions must then focus on the promotion of efficient referral pathways and organizational models that deliver expert care and the necessary workforces and digital infrastructures. Examples of national expert centre networks include those in France and Spain.4 Genetic testing plays an increasing role in cardiomyopathy care and is recommended to optimize patient care and family screening (in conjunction with clinical screening).2 In addition, genetics could offer a path towards precision medicine for cardiomyopathies, with gene editing and gene therapy techniques already under investigation.5 A causative pathogenic variant can be identified in around 20%–60% of probands with the main four types of cardiomyopathy, i.e. hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, and restrictive cardiomyopathy.2 Patients and families should have reimbursed access to genetic counselling by a suitably trained healthcare professional (before and after testing) to help them deal with the potential implications of these tests. Indeed, genetic counselling is recommended for everyone with an inherited or suspected inherited cardiomyopathy, regardless of whether they decide to undergo testing. Promoting family screening is vital to drive early diagnosis. First-degree relatives of the patients should be offered clinical screening, with genetic testing offered if a disease-causing variant has been identified in the index patient.2 Genetic testing of family members can be cost-effective, by excluding the presence of genetic variants and thereby avoiding the need for follow-up. Despite the increasing recognition of their impact, genetic counselling and testing are often underused,2,6 with substantial variations between and within countries, creating disparities in access. According to a systematic review and meta-analysis, only half to three-quarters of patients with hypertrophic cardiomyopathy and their relatives undergo genetic testing or cascade screening, and the uptake of genetic counselling is highly variable, despite being associated with high satisfaction and improved patient-reported outcomes.7 Other estimates suggest that overall genetic testing is performed in only 1%–2% of cardiomyopathy cases.8 Further variations exist in the availability of prenatal or pre-implantation genetic diagnosis to inform family planning.9 Policy actions necessary to ensure appropriate access to genetic testing and counselling (Figure 1) include measures to promote adherence to ESC clinical guidelines, policies and resourcing that support reimbursement based on guidelines, and sufficient resourcing to provide adequate levels of genetic workforce and laboratory capacity—something few countries achieve at present.10 Leveraging the value of genetics and other disease management advances also requires investment in systems for collection, analysis, and sharing of good-quality, harmonized, secure data to help optimize individual patient care, drive quality improvement, and support research and innovation. Cardiomyopathies can present many challenges for patients and families, including morbidity, fears about sudden cardiac death, implications for daily activities, and concerns about inheritance. Holistic psychosocial support is therefore an important part of multidisciplinary cardiomyopathy care.2 Patients and carers play key roles in managing their conditions. National actions are necessary to empower them through measures that promote shared decision-making and self-care, including providing them with access and control over their own electronic health data (Figure 1). More broadly, empowerment efforts should extend to patients and carers’ involvement in decision-making regarding relevant healthcare policies, services, technologies, and research priorities. Policymakers should recognize and promote the role played by patient organizations in these matters. National measures should also include campaigns to raise public awareness of inherited cardiovascular diseases, including cardiomyopathies, and associated symptoms and risks. Promoting public training in cardiopulmonary resuscitation and the use of automated external defibrillators is also vital, coupled with adequate and equitable access to these devices in public spaces. After decades of focus on coronary disease and its related risk factors, it is time to concentrate efforts and resources on genetic diseases, which are more prevalent than previously thought, disproportionately affect the young, and now are potential targets for an increasing number of innovative therapies. The Cardiomyopathies Matter initiative aims to take an important step in this direction by informing policy changes that improve outcomes for patients and families affected by cardiomyopathies, including inherited forms. European Union–level measures already play a major role, including support for the GUARD Heart European Reference Network and research projects. We have recommended further EU-level measures, including a Cardiovascular Health Mission and Action Plan, leveraging the European Health Data Space, establishment of a European Cardiovascular Health Data Knowledge Centre, alignment of data sharing policies, and further research funding.4 We encourage cardiologists and allied healthcare professionals across Europe to collaborate with patient organizations and policymakers at all levels to promote national health policies that ensure all patients and families have access to guideline-informed care—Cardiomyopathies Matter initiatives are now in progress in many countries to this end. The authors thank Tomasz Hryniewiecki and Przemysław Leszek (National Institute of Cardiology, Warsaw, Poland) for the additional information included in Table 1. T.B. declares consulting fees from BMS and Alnylam; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Alnylam; and support for attending meetings and/or travel (BMS). T.B. is a trustee of Cardiomyopathy UK and a member of its Clinical Expert Advisory Group. P.G.-P. declares grants or contracts from any entity (paid to institution) from Pfizer, Bridgebio, NovoNordisk, AstraZeneca, Intellia, and Alnylam Pharmaceuticals; consulting fees from BMS, Cytokinetics, Rocket Pharmaceuticals, Lexeo, Pfizer, Bridgebio, Daiichi Sankyo, Neuroimmune, Alnylam Pharmaceuticals, AstraZeneca, NovoNordisk, ATTRalus, Intellia, Idoven, General Electric, and Alexion; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MS, Pfizer, Bridgebio, Ionis Pharmaceuticals, AstraZeneca, NovoNordisk, Intellia, and Alnylam Pharmaceuticals; and support for attending meetings and/or travel from Pfizer and Alnylam. S.M. declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from BMS. E.C. declares consulting fees and support for attending meetings and/or travel (paid to institution) from BMS. M.P. declares support for attending meetings and/or travel (paid to institution) from BMS. P.T. declares support for attending meetings and/or travel (paid to institution) from BMS. S.J. declares consulting fees from BMS and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events (to organization) from BMS. I.O. declares grants or contracts (paid to institution) from BMS, Cytokinetics, Amicus, Genzyme, Takeda, Tenaya, Rocket Pharma, Lexeo, Chiesi, Boston Scientific, and Menarini International; consulting fees from BMS, Cytokinetics, Amicus, Genzyme, Takeda, Chiesi, Rocket Pharma, and Lexeo; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from BMS and Cytokinetics; support for attending meetings and/or travel from BMS, Rocket Pharma, Cytokinetics, and Bayer; and participation on Data Safety Monitoring Board or Advisory Board for BMS, Cytokinetics, and Rocket Pharma. M.T.T. declares consulting fees from BMS and Cytokenetics and participation on Data Safety Monitoring Board or Advisory Board for BMS and Cytokinetics. J.N.T. declares consulting fees from Abbott, AstraZeneca, BMS, and Novartis and support for attending meetings and/or travel from AstraZeneca. R.V. declares support for attending meetings and/or travel from BMS and participation on Data Safety Monitoring Board or Advisory Board for Holland Hybrid Heart, Arena-Prime, and RegMedXB. R.V. is co-founder of LMNA Cardiac Foundation. S.T. declares support for attending meetings and/or travel (paid to institution) from BMS and Merck/MSD. T.F. declares support for attending meetings and/or travel (paid to institution) from BMS. L.B. is a senior advisor at Dentons Global Advisors. Dentons Global Advisors provides the secretariat function for the Cardiomyopathies Matter Secretariat, which is funded by BMS. Cardiomyopathies Matter is funded by Bristol Myers Squibb. Nothing contained herein is intended, nor should be interpreted, to promote BMS nor any BMS product or agent. Editorial control for this article rests with the authors. Cardiomyopathies Matter is currently working to extend its funder base to involve additional partners. Cardiomyopathies Matter initiative contributors: Teofila (Tootie) Bueser (South East Genomic Medicine Service Alliance, Guy’s & St Thomas’ NHS Foundation Trust and North Thames Genomic Medicine Service Alliance, Great Ormond Street Hospital NHS Foundation Trust, London, UK), Ester Costafreda [Asociación para Pacientes y Familiares con Síndromes Arrítmicos relacionados con la Muerte Súbita (SAMS), Spain], Tomás Fajardo (Cardioalanza, Spain), Pablo Garcia-Pavia (Inherited Cardiac Diseases and Heart Failure Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain), Stefan Janssens (Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium), Hugo Katus (Department of Internal Medicine III—Cardiology, Angiology, and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany), Stellan Mörner (Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden), Iacopo Olivotto (Department of Experimental and Clinical Medicine, University of Florence and Meyer University Children Hospital, Florence, Italy), Matteo Pinciroli [Cardiomyopathy Patient Council, Global Heart Hub and Italian Association for the Study and Research of Cardiomyopathies (AICARM)], Sean Taylor (World Heart Federation, Geneva, Switzerland), Maria T. Tome Esteban (Cardiovascular Clinical Academic Group, Inherited Cardiac Condition Service, St George’s Hospital NHS Foundation Trust and St George’s University of London, London, UK), Patricia Tiramani (Global Heart Hub, Galway, Ireland), Jean-Noël Trochu (Thorax Institute, Heart Failure and Cardiomyopathies Unit, University Hospital, Nantes, France), Rogier Veltrop (LMNA Lab Mechanobiochemistry and Cardiac Cell Signalling, Cardiovascular Research Institute Maastricht, Maastricht University, and LMNA Cardiac Foundation, Maastricht, The Netherlands), Lee Baker (Cardiomyopathies Matter Secretariat, Brussels, Belgium).
No takes yet. Share an insight, caveat, or question.
Olivotto et al. (2024) conducted a review in Cardiomyopathies. National health policies and guideline-led care was evaluated. National and European health policies are needed to ensure patients and families affected by cardiomyopathies have access to multidisciplinary expert care, genetic testing, and holistic support.
Synapse has enriched 10 related papers. Consider them for comparative context: